Chronic diarrhea in patients with Clostridium difficile infection in association with COVID-19
Keywords:
COVID-19, SARS-CoV-2, C.difficile infection, chronic diarrhea, risk factorsAbstract
Clostridium difficile infection (CDI) is a complication of COVID-19 infection, caused by alteration of the microbiome during long-term administration of broad-spectrum antibiotics. Excessive administration of antibiotics in patients with COVID-19 causes a change in the eubiosis of the microbiota in the respiratory and gastrointestinal tract. Alteration of the fecal microbiota composition in patients with COVID-19 is associated with an increase in the number of opportunistic pathogens and a decrease in beneficial diners. C. difficile is a pathogenic organism that is responsible for most cases of antibiotic-associated diarrhea. Empirical administration of antibiotics and non-steroidal anti-inflammatory drugs, recent history of healthcare exposure, the presence of comorbidities such as cardiovascular disease or diabetes associated with age over 65 years are predisposing factors for CDI in patients with COVID-19.
References
1. US Centers for Disease Control and Prevention. Interim clinical guidance for management of patients with confirmed coronavirus disease (COVID-19) [cited 2020 May 1]. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management
2. GUAN, WJ. et al. China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. In: N Engl J Med. 2020, 382, pp.1708-20. https://doi.org/10.1056/NEJMc2005203
3. CHEN, N. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.In: Lancet. 2020, 395, pp.507-13. https://doi.org/10.1016/S0140-6736(20)30211-7
4. WANG, D. et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. In: JAMA. 2020, 323, pp.1061-9. https://doi.org/10.1001/jama.2020.1585
5. MAO, R. et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. In: Lancet Gastroenterol. Hepatol. 2020 ,5,pp. 667-678. https://doi.org/10.1016/S2468-1253(20)30126-6
6. CHEN, T. et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. In: BMJ. 2020, nr.368.
7. BROWN, KA. et al,. Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection.In:Antimicrob Agents Chemother. 2013,57, pp. 2326-32. https://doi.org/10.1128/AAC.02176-12
8. AZIMIRAD, M. et al. Clostridioides difficile ribotypes 001 and 126 were predominant in Tehran healthcare settings from 2004 to 2018: a 14-year-long cross-sectional study. In: Emerg Microbes Infect. 2020 Dec;9(1), pp. 1432-1443. https://doi.org/10.1080/22221751.2020.1780949
9. LU, R. et al. Genomic characterisation and epidemiology of 2019 novel coronavirus:implications for virus origins and receptor binding. In: Lancet . 2020, 395, pp. 565-574.
10. GEORGE, WL. et al. Aetiology of antimicrobial-agentassociated colitis. In: Lancet. 1978 15 aprilie.
11. SMITH, AB., SOTO, OCANA, J., ZACKULAR, JP. From Nursery to Nursing Home: Emerging Concepts in Clostridioides difficile Pathogenesis. In: Infect Immun. 2020, 22 iunie, p. 88. https://doi.org/10.1128/IAI.00934-19
12. LESSA, FC. et al. Burden of Clostridium difficile Infection in the United States. In: N Eng J Med. 2015, 372, pp. 825-834.
https://doi.org/10.1056/NEJMoa1408913
13. HENDAUS, MA., JOMHA, FA. Covid-19 induced superimposed bacterial infection. In: J Biomol Struct Dyn. 2021,pp: 4185-4191. https://doi.org/10.1080/07391102.2020.1772110
14. WU, A. et al. Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. In: Cell Host Microbe. 2020, 27,pp. 325-328. https://doi.org/10.1016/j.chom.2020.02.001
15. LETKO, M., MARZI. A., MUNSTER, V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. In: Nat Microbiol. 2020 ,pp. 562-569. https://doi.org/10.1038/s41564-020-0688-y
16. SHANG, J. et al. Structural basis of receptor recognition by SARS-CoV-2. In: Nature 2020, 581, pp. 221-224. https://doi.org/10.1038/s41586-020-2179-y
17. OU, T. et al. Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2. In: PLoS Pathog. 2020,nr.17. e1009212 https://doi.org/10.1371/journal.ppat.1009212
18. WEIBEL, E. R. Morphometry of the human lung: the state of the art after two decades.In: Bull Eur Physiopathol Respir. 1979, nr. 15, pp. 999-1013.
19. SUÁREZ-FARIÑAS, M. et al. Intestinal inflammation modulates the expression of ACE2 and TMPRSS2 and potentially overlaps with the pathogenesis of SARSCoV-2-related disease. In : Gastroenterology. 2021, nr.160,pp. 287-301. https://doi.org/10.1053/j.gastro.2020.09.029
20. GUO, M. et al. Potential intestinal infection and faecaloral transmission of SARS-CoV-2. In: Nat. Rev. Gastroenterol. Hepatol. 2021, nr.18, pp. 269-283. https://doi.org/10.1038/s41575-021-00416-6
21. LIN, W. et al. Association between detectable SARSCOV-2 RNA in anal swabs and disease severity in patients with coronavirus disease 2019. In : J. Med. Virol. 2021 , nr.93,pp.794-802. https://doi.org/10.1002/jmv.26307
22. XIAO, F. et al. Evidence for gastrointestinal infection of SARS-CoV-2. In: Gastroenterology. 2020, nr.158, pp.1831-1833. https://doi.org/10.1053/j.gastro.2020.02.055
23. LIN, L. et al. Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection.In :Gut. 2020,nr.69, pp.997-1001. https://doi.org/10.1136/gutjnl-2020-321013
24. GUARNER, F. & MALAGELADA, J. R. Gut flora in health and disease. In: Lancet.2003 ,nr.361,pp. 512-519. https://doi.org/10.1016/S0140-6736(03)12489-0
25. BELKAID, Y., HAND, T. Role of the microbiota in immunity and inflammation. In: Cell. 2015,nr.157(1), pp.121-141. https://doi.org/10.1016/j.cell.2014.03.011
26. COSTELA-RUIZ, VJ. et al. SARS-CoV-2 infection: the role of cytokines in COVID-19 disease.In: Cytokine Growth Factor Rev. 2020. nr.54,pp.62-75 https://doi.org/10.1016/j.cytogfr.2020.06.001
27. WEAVER, LK. et al. Microbiota-dependent signals are required to sustain TLR-mediated immune responses. In: JCI Insight. 2019, nr.4(1), pp.1-9. https://doi.org/10.1172/jci.insight.124370
28. YEOH, YK. et al. Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19.In: Gut. 2021.nr.70(4), pp.698-706. https://doi.org/10.1136/gutjnl-2020-323020
29. TANG, L. et al. Clinical significance of the correlation between changes in the major intestinal bacteria species and COVID-19 severity.In:Engineering. 2020. nr.6(10), pp.1178-1184. https://doi.org/10.1016/j.eng.2020.05.013
30. KHATIWADA, S., SUBEDI, A. Lung microbiome and coronavirus disease 2019 (COVID-19): possible link and implications. In: Hum Microb J.2020,nr.17. https://doi.org/10.1016/j.humic.2020.100073
31. VAN DER LELIE, D., TAGHAVI, S. COVID-19 and the Gut Microbiome: More than a Gut Feeling. In: mSystems. 2020, 21 iulie ,nr. 5(4), e00453-20 https://doi.org/10.1128/mSystems.00453-20
32. ZUO, T. et al. Alterations in gut Microbiota of patients with COVID-19 during time of hospitalization.In :Gastroenterology. 2020, nr.159, pp.944-55. https://doi.org/10.1053/j.gastro.2020.05.048
33. ZUO, T. et al. Depicting SARS-CoV-2 faecal viral activity in association with gut microbiota composition in patients with COVID-19. In: Gut. 2020. https://doi.org/10.1136/gutjnl-2020-322294
34. LUO, Y., GRINSPAN, LT., FU, Y. et al. Hospital-onset Clostridioides difficile infections during the COVID-19 pandemic. In: Infect.Control Hosp.Epidemiol. 2020, Sep, nr.42(9),pp.1165-1166. https://doi.org/10.1017/ice.2020.1223
35. KALINKOVICH, A., LIVSHITS, G. A cross talk between dysbiosis and gutassociated immune system governs the development of inflammatory arthropathies. In: Semin Arthritis Rheum. 2019.Dec, nr.49(3), pp.474-484. https://doi.org/10.1016/j.semarthrit.2019.05.007
36. SCHMULSON, M., GHOSHAL, UC., BARBARA, G. Managing the inevitable surge of post-COVID-19 functional gastrointestinal disorders. In: Am J Gastroenterol. 2021.nr. 116(1), pp.4-7. https://doi.org/10.14309/ajg.0000000000001062
37. YOON, MY., YOON, SS. Disruption of the gut ecosystem by antibiotics. In: Yonsei Med J. 2018.nr. 59, pp.4-12. https://doi.org/10.3349/ymj.2018.59.1.4
38. HORVAT, S., RUPNIK, M. Interactions between clostridioides difficile and fecal microbiota in in vitro batch model: growth, sporulation, and microbiota changes. Front Microbiol. 2018, nr.9, p.1633. https://doi.org/10.3389/fmicb.2018.01633
39. LASZKOWSKA, M. et al. Prevalence of Clostridioidesdifficile and other gastrointestinal pathogens in patients with COVID-19. In: Dig Dis Sci. 2021. Dec, nr.66(12), pp.4398-4405 https://doi.org/10.1007/s10620-020-06760-y
40. CHUNXI, LI. et al. The gut microbiota and respiratory diseases: new evidence. In: J Immunol Res. 2020.31 iulie. https://doi.org/10.1155/2020/2340670
41. BENTIVEGNA, E. et al. Reduction of multidrug-resistant (MDR) bacterial infections during the COVID-19 pandemic: a retrospective study. In: Int J Environ Res Public Health. 2021, nr.18, p.1003. https://doi.org/10.3390/ijerph18031003
42. SANDHU, A. et al. Clostridioides difficile in COVID-19 Patients, Detroit, Michigan, USA, March-April 2020. In: Emerg. Infect. Dis. 2020, 26(9),pp. 2299-2300. https://doi.org/10.3201/eid2609.202505
43. LUCIANI, M. et al. Coinfection of tuberculosis pneumonia and COVID-19 in a patient vaccinated with Bacille Calmette-Guérin (BCG): case report. In: SN Compr Clin Med. 2020, nr.2, pp.2419-2422. https://doi.org/10.1007/s42399-020-00601-9
44. LUCIANI, M. et al. Recurrent COVID-19 pneumonia in the course of chemotherapy:consequence of a weakened immune system. In: J Med Virol. 2021, nr.93, pp.1882-1884. https://doi.org/10.1002/jmv.26701
45. LOPETUSO, LR. et al. The impact of COVID-19 pandemic on IBD endoscopic procedures in a highvolume IBD Center.In: Endosc Int Open. 2020, nr.8, pp.980-84. https://doi.org/10.1055/a-1183-3073
46. YACOUBA, A., OLOWO-OKERE, A., YUNUSA, I. Repurposing of antibiotics for clinical management of COVID-19: a narrative review. In: Ann Clin Microbiol Antimicrob. 2021,nr. 20, p.37. https://doi.org/10.1186/s12941-021-00444-9
47. HUTTNER ,BD. et al. COVID-19:don't neglect antimicrobial stewardship principles. In: Clin Microbiol Infect.2020, nr.26, pp.808-810. https://doi.org/10.1016/j.cmi.2020.04.024
48. FERREIRA, EO., PENNA, B., YATES, EA. Should we be worried about Clostridioides difficile during the SARS-CoV2 pandemic? In:Front Microbiol.2020, 29 sep. nr.11:581343. https://doi.org/10.3389/fmicb.2020.581343
49. LIBERTINI, G. et al. Age-related dysfunctions:evidence and relationship with some risk factors and protective drugs. In: Biochemistry. 2019,nr. 84, pp.1442-1450. https://doi.org/10.1134/S0006297919120034
50. KANG, SJ., JUNG, SI. Age-related morbidity and mortality among patients with COVID-19. In: Infect Chemother. 2020,nr. 52, pp.154-64. https://doi.org/10.3947/ic.2020.52.2.154
51. WANG, W., TANG,J., WEI, F. Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China. In: J Med Virol. 2020, nr.92, pp.441-447. https://doi.org/10.1002/jmv.25689
52. GRANATA, G. et al. The burden of clostridioides difficile infection during the COVID-19 pandemic: a retrospective case-control study in italian hospitals (CloVid).In: J Clini Med. 2020, nr.9,p.3855. https://doi.org/10.3390/jcm9123855
53. ALGHATRIF M, CINGOLANI O, LAKATTA EG. The dilemma of coronavirus disease 2019, aging, and cardiovascular disease: insights from cardiovascular aging science. In: JAMA Cardiol. 2020, nr.5, pp.747-8. https://doi.org/10.1001/jamacardio.2020.1329
54. LOO, VG. et al. Host and pathogen factors for Clostridium difficile infection and colonization. In: N Engl J Med. 2011, nr.365, pp.1693-1703. https://doi.org/10.1056/NEJMoa1012413
55. DONSKEY, CJ. Clostridium difficile in older adults.In: Infect Dis Clin North Am. 2017 nr.31,pp.743-756. https://doi.org/10.1016/j.idc.2017.07.003
56. MICALLEF, J., SOEIRO, T., ANNIE-PIERRE, JB. Nonsteroidal anti-inflammatory drugs, pharmacology, and COVID-19 infection. In: Therapie. 2020,nr.75, pp.355-362. https://doi.org/10.1016/j.therap.2020.05.003
57. WONGRAKPANICH, S. et al. A comprehensive review of non-steroidal anti-inflammatory drug use in the elderly.In: Aging Dis. 2018,nr. 9,pp.143-150. https://doi.org/10.14336/AD.2017.0306
58. ESBA, LCA. et al. Ibuprofen and NSAID use in COVID-19 infected patients is not associated with worse outcomes: a prospective cohort study. In: Infect Dis Ther. 2021, nr. 10, pp. 253-268. https://doi.org/10.1007/s40121-020-00363-w
59. MASEDA, D. et al.Nonsteroidal anti-inflammatory drugs alter the microbiota and exacerbate clostridium difficile colitis while dysregulating the inflammatory response. In: mBio. (2019) vol. 10:e02282-18. https://doi.org/10.1128/mBio.02282-18
60. NOORI, M., YADEGAR, A., ZALI, MR. A complex scenario of nonsteroidal anti-inflammatory drugs induced prostaglandin E2 production and gut microbiota alteration in clostridium difficile-infected mice.In: mBio.2020.vol.11:e02596-19. https://doi.org/10.1128/mBio.02596-19
61. SUISSA, D. et.al. Non-steroidal anti-inflammatory drugs and the risk of Clostridium difficile-associated 375
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
